Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LODEXA: Low-Dose Dexamethasone to Prevent CRS in Tebentafusp-Treated Uveal Melanoma
NCT07803562Phase 2Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexamethasone in cytokine release syndrome (CRS), sponsored by University of California, San Diego. Primary endpoint: Incidence of Grade >=2 Cytokine Release Syndrome at 3 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT07803562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803562.